HIV infection as a risk factor for COVID 19: A systematic review and meta-analysis
There are many questions about the behavior of coronavirus disease 2019 (COVID-19) in people living with human Immunodeficiency virus (PLHIV). It is not clear whether they have a higher risk of complications or higher mortality than the general population. The risk of infection of Severe acute respi...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Asociación Colombiana de Infectología,
2023-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_0ab0c2098f7d4ffc966f7afd3fe96560 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Silvia Juliana Vásquez-Lozano |e author |
| 245 | 0 | 0 | |a HIV infection as a risk factor for COVID 19: A systematic review and meta-analysis |
| 260 | |b Asociación Colombiana de Infectología, |c 2023-01-01T00:00:00Z. | ||
| 500 | |a https://doi.org/10.22354/24223794.1114 | ||
| 500 | |a 0123-9392 | ||
| 520 | |a There are many questions about the behavior of coronavirus disease 2019 (COVID-19) in people living with human Immunodeficiency virus (PLHIV). It is not clear whether they have a higher risk of complications or higher mortality than the general population. The risk of infection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), risk of severe symptoms by COVID-19, and risk of mortality by COVID-19 of PLHIV were compared with people without human im-munodeficiency virus (HIV). EMBASE, PubMed, Scopus, Cochrane Library, Web of Science, LILACS and SCIELO were searched from January 2020 to March 2021. 22 cohort / case-control studies were chosen. Software Review Manager 5.4 was used for the meta-analysis. An increased risk of mortality (2.07) due to COVID-19 was identified among people with human immudeficiency virus (HIV) compared to people without HIV. HIV infection is a risk factor for COVID-19; it should be given special to patients with high viral load, low count CD4 and who are not currently receiving antiviral therapy (ART). | ||
| 546 | |a EN | ||
| 546 | |a ES | ||
| 690 | |a covid-19 | ||
| 690 | |a sars-cov-2 | ||
| 690 | |a hiv | ||
| 690 | |a plhiv | ||
| 690 | |a art | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 690 | |a Infectious and parasitic diseases | ||
| 690 | |a RC109-216 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Infectio, Vol 27, Iss 1, Pp 15-22 (2023) | |
| 787 | 0 | |n https://doaj.org/toc/0123-9392 | |
| 856 | 4 | 1 | |u https://doaj.org/article/0ab0c2098f7d4ffc966f7afd3fe96560 |z Connect to this object online. |